Financial Lp Hrt Sells 9,022 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 9,022 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $3.51, for a total value of $31,667.22. Following the completion of the transaction, the insider directly owned 81,385 shares in the company, valued at approximately $285,661.35. This trade represents a 9.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, July 2nd, Financial Lp Hrt purchased 7,851 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average price of $3.54 per share, for a total transaction of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt acquired 3,959 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average cost of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average price of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average cost of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Trading Up 9.5%

Shares of SHPH opened at $3.57 on Thursday. Shuttle Pharmaceuticals Holdings, Inc. has a 1 year low of $2.90 and a 1 year high of $55.90. The stock has a market cap of $2.28 million, a P/E ratio of -0.07 and a beta of 0.29. The stock’s 50-day moving average price is $5.30 and its two-hundred day moving average price is $10.27.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

Several large investors have recently modified their holdings of the business. Connective Capital Management LLC bought a new position in shares of Shuttle Pharmaceuticals during the 3rd quarter valued at about $357,000. Ikarian Capital LLC acquired a new stake in Shuttle Pharmaceuticals during the 4th quarter worth approximately $124,000. Boothbay Fund Management LLC acquired a new stake in Shuttle Pharmaceuticals during the 4th quarter worth approximately $37,000. Finally, Geode Capital Management LLC bought a new position in Shuttle Pharmaceuticals in the fourth quarter valued at approximately $26,000. 4.58% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

SHPH has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .